<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04928105</url>
  </required_header>
  <id_info>
    <org_study_id>Senl-T7 CART for CD7+ lymphoma</org_study_id>
    <nct_id>NCT04928105</nct_id>
  </id_info>
  <brief_title>Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma</brief_title>
  <official_title>Clinical Study of Senl-T7 CAR-T Cells in the Treatment of Relapsed or Refractory CD7+ Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Senlang Biotechnology Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Senlang Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open and prospective clinical study, taking patients with relapsed or&#xD;
      refractory CD7+ lymphoma as the test subjects, in order to evaluate the safety and efficacy&#xD;
      of Senl-T7 CAR-T for patients with CD7+ lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main research purposes:&#xD;
&#xD;
      To evaluate the safety and efficacy of Senl-T7 CAR-T for relapsed or refractory CD7+ lymphoma&#xD;
&#xD;
      Secondary research purpose:&#xD;
&#xD;
      To investigate the cytokinetic characteristics of Senl-T7 CAR-T for relapsed or refractory&#xD;
      CD7+ lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence and severity of adverse events</measure>
    <time_frame>First 1 month post CAR-T cells infusion</time_frame>
    <description>To evaluate the possible adverse events occurred within first one month after CD7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission Rate</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>Remission Rate including complete remission(CR)、CR with incomplete blood count recovery(CRi)、No remission(NR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>duration of response (DOR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>progression-free survival (PFS) time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CAR-T proliferation</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>the copy number of CD7 CAR- T cells in the genomes of PBMC by qPCR method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CAR-T proliferation</measure>
    <time_frame>3 months post CAR-T cells infusion</time_frame>
    <description>percentage of CD7 CAR- T cells measured by flow cytometry method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine release</measure>
    <time_frame>First 1 month post CAR-T cells infusion</time_frame>
    <description>Cytokine( IL-6,IL-10,IFN-γ,TNF-α ) concentration (pg/mL) by flow cytometry method</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>SenL-T7 CAR T Cells CD7+ Lymphoma</condition>
  <arm_group>
    <arm_group_label>CD7 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Senl-T7</intervention_name>
    <description>Patients will be treated with CD7 CAR-T cells</description>
    <arm_group_label>CD7 CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Diagnosed as relapsed or refractory lymphoma; 2. Tumor cells express CD7 (express&#xD;
             CD7 by flow cytometry or immunohistochemistry); 3. The expected survival period is&#xD;
             greater than 12 weeks; 4. KPS or Lansky score ≥60; 11 5. Age 2-70 years old; 6.&#xD;
             HGB≥70g/L (can be transfused); 7. Indoor blood oxygen saturation&gt; 90%; 8. Total&#xD;
             bilirubin does not exceed 3 times the upper limit of normal value, and AST and ALT do&#xD;
             not exceed 5 times the upper limit of normal value; 9. The subject or guardian&#xD;
             understands and signs the informed consent form;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. One of the following cardiac criteria: atrial fibrillation; myocardial infarction&#xD;
             within the past 12 months; prolonged QT synthesis Syndrome or secondary QT&#xD;
             prolongation is at the discretion of the investigator. Echocardiography LVSF&lt;30% or&#xD;
             LVEF&lt; 50%; clinically significant pericardial effusion; cardiac insufficiency NYHA&#xD;
             (New York Heart Association) III or IV (the absence of this symptom confirmed by&#xD;
             echocardiography within 12 months after treatment); 2. There is active GVHD; 3. Have a&#xD;
             history of severe pulmonary dysfunction diseases; 4. Merge other malignant tumors in&#xD;
             advanced stage; 5. Combined with severe infection or persistent infection and cannot&#xD;
             be effectively controlled; 6. Combined with severe autoimmune disease or congenital&#xD;
             immunodeficiency; 7. Active hepatitis (hepatitis B virus deoxyribonucleic acid&#xD;
             [HBVDNA] or hepatitis C virus ribonucleic acid [HCVRNA] test positive); 8. Human&#xD;
             immunodeficiency virus (HIV) infection or syphilis infection or HTLV infection; 9.&#xD;
             There is a history of severe allergies to biological products (including antibiotics);&#xD;
             10. Clinically significant viral infection, or uncontrollable viral reactivation,&#xD;
             including EBV (Epstein-Barr virus), CMV (cytomegalovirus), ADV (adenovirus), BKV,&#xD;
             HHV(human herpesvirus)-6; 11. There are central nervous system disorders, such as&#xD;
             uncontrolled epilepsy, cerebrovascular ischemia/hemorrhage, dementia, Cerebellar&#xD;
             diseases, etc.; 12. Female patients are pregnant and lactating, or have a pregnancy&#xD;
             plan within 12 months; 13. Circumstances that the researcher believes may increase the&#xD;
             risk of the subject or interfere with the results of the test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peihua MD Lu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peihua MD Lu, PhD</last_name>
    <phone>008618611636172</phone>
    <email>peihua_lu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianqiang MD Li, PhD</last_name>
    <phone>008615511369555</phone>
    <email>limmune@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hebei yanda Ludaopei Hospital</name>
      <address>
        <city>Yanda</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peihua MD Lu, PhD</last_name>
      <phone>008618611636172</phone>
      <email>peihua_lu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

